Ghrelin promotes cardiomyocyte differentiation of adipose tissue-derived mesenchymal stem cells by DDX17-mediated regulation of the SFRP4/Wnt/β-catenin axis

GUI-BO LIU¹, YONG-XIA CHENG², HUA-MIN LI³, YONG LIU⁴, LI-XIN SUN⁵, QI WU², SHANG-FU GUO⁶, TING-TING LI⁷, CHUAN-LING DONG¹ and GE SUN⁸

¹Department of Anatomy, School of Basic Medical Sciences, Mudanjiang Medical University; ²Department of Pathology, The First Clinical Medical School of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011; ³Department of Pathology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157000; ⁴Department of Research Platform, Mudanjiang Medical University; ⁵Office of Educational Administration, Mudanjiang Medical University; ⁶Department of Asset Management, Mudanjiang Medical University; ⁷Department of Pathology, School of Basic Medical Sciences, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011; ⁸Department of Orthopedics, The Second Affiliated Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157010, P.R. China

Received March 3, 2023; Accepted June 5, 2023

DOI: 10.3892/mmr.2023.13050

Abstract. Adipose tissue-derived mesenchymal stem cells (ADMSCs) differentiate into cardiomyocytes and may be an ideal cell source for myocardial regenerative medicine. Ghrelin is a gastric-secreted peptide hormone involved in the multilineage differentiation of MSCs. To the best of our knowledge, however, the role and potential downstream regulatory mechanism of ghrelin in cardiomyocyte differentiation of ADMSCs is still unknown. The mRNA and protein levels were measured by reverse transcription-quantitative PCR and western blotting. Immunofluorescence staining was used to show the expression and cellular localization of cardiomyocyte markers and β-catenin. RNA sequencing was used to determine the DEGs regulated by ghrelin. Functional enrichment showed that DEGs were more enriched in cardiomyocyte differentiation-associated terms and Wnt pathways. Dead-box helicase 17 (DDX17), an upregulated DEG, showed enhanced mRNA and protein expression levels following ghrelin addition. Overexpression of DDX17 promoted protein expression of cardiac-specific markers and β-catenin and enhanced the fluorescence intensity of α-MHC and β-catenin. DDX17 upregulation inhibited protein expression of SFRP4. Rescue assay confirmed that the addition of SFRP4 partially reversed ghrelin-enhanced protein levels of cardiac-specific markers and the fluorescence intensity of α-MHC. In conclusion, ghrelin promoted cardiomyocyte differentiation of ADMSCs by DDX17-mediated regulation of the SFRP4/Wnt/β-catenin axis.

Introduction

Mesenchymal stem cells (MSCs) are stromal cells with self-renewal and multilineage differentiation ability isolated from tissue. Adipose tissue-derived MSCs (ADMSCs) are the
preferred SCs for clinical applications due to their convenient acquisition and easy culture (1). Studies have shown that ADMSCs can differentiate into cardiomyocyte and are an ideal cell source for myocardial regenerative medicine (2,3).

Ghrelin, a gastric-secreted peptide hormone, was first isolated and identified in the rat stomach in 1999 and is an endogenous ligand for the growth hormone secretagogue receptor (4,5). Ghrelin is involved in and regulates a variety of physiological processes, including energy balance and weight maintenance and studies have shown strong associations between ghrelin and the cardiovascular system (6-8). In addition, ghrelin is involved in the multilineage differentiation of MSCs. Our previous study showed that ghrelin serves a critical role in the promotion of neural differentiation of ADMSCs (9). Studies have shown that ghrelin inhibits cardiomyocyte apoptosis and improves myocardial infarction (10,11). Pretreatment of MSCs with ghrelin exerts a protective effect in aged hearts (12). Studies have also found that ghrelin can promote differentiation of embryonic SCs into cardiomyocytes (13,14). The aforementioned studies suggest that ghrelin serves a key role in the differentiation of MSCs. However, it is still unknown whether ghrelin affects the differentiation of ADMSCs into cardiomyocyte.

Studies have reported the essential role of Wnt/β-catenin signaling pathway in embryonic heart development and in vitro cardiomyocyte differentiation (15,16). Ghrelin could regulate cell apoptosis, proliferation and function via activation of Wnt/β-catenin pathway in a variety of cells and tissue (17). Secreted frizzled-related protein 4 (SFRP4) inhibits Wnt signaling by competing with frizzle-protein receptor, a specific receptor of the Wnt signaling pathway (18,19). It has been reported that SFRP4 promotes adipogenic differentiation of ADMSCs and inhibits the osteogenic differentiation of human periodontal ligament MSCs (20,21). SFRP4 inhibits the expression of cardiac-specific genes during differentiation of iP19CL6 cells, a clonal derivative of murine P19 cells, into cardiomyocytes (22). Therefore, it was hypothesized that ghrelin may promote ADMSC cardiomyocyte differentiation by regulating the SFRP4/Wnt/β-catenin axis. To explore the regulatory mechanism of ghrelin in regulating SFRP4/Wnt/β-catenin axis, the present used RNA sequencing (seq) of cultured ADMSCs to identify potential genes regulated by ghrelin.

Accordingly, the aim of the present study was to investigate the critical role of ghrelin in cardiomyocyte differentiation of ADMSCs and the potential downstream regulatory mechanisms.

Materials and methods

Cell culture. Human ADMSCs were purchased from Cyagen Biosciences, Inc. (cat. no. HUXMD-01001). Cells were cultured in ADMSC complete medium (cat. no. HUXMD-90011; Cyagen Biosciences, Inc.) in an incubator at 37˚C with 5% CO2.

Immunophenotyping analysis. Cell surface markers were identified by flow cytometry. Cells were collected by centrifugation (90 x g; 5 min; 4˚C). The cells of the 3rd to 5th generation were trypsinized (cat. no. T4799; MilliporeSigma). When the cells became round, FBS-containing ADMSC complete medium was added to stop the reaction, cells were collected by centrifugation (90 x g; 5 min; 4˚C) and the density was adjusted to 1x10⁶ cells/ml. Cells were added to labeled antibodies, including the control, to a final volume of 100 µl. After being incubated at 4˚C for 30 min, 1 ml buffer was added to each tube. The cells were collected by centrifugation (90 x g; 5 min; 4˚C) and resuspended in 500 µl buffer before testing. Analysis was performed using the NovoExpress software (version 1.4.1) based on a NovoCyte flow cytometer (ACEA Bioscience, Inc.; Agilent Technologies, Inc.). Antibodies were as follows: CD29 (cat. no. CL488-65191; mouse; Proteintech Group, Inc.), CD90-FITC (cat. no. 328107; mouse; Biolegend, Inc.), CD34-FITC (cat. no. FITC-65183; mouse; Proteintech Group, Inc.), CD45-FITC (cat. no. AH04501; mouse; Multi Sciences), CD11b-FITC (cat. no. AH011B01; rat; Multi Sciences), CD44-FITC (cat. no. AH04401; rat; Multi Sciences).

Multilineage differentiation of ADMSCs. To evaluate the multilineage differentiation potential of ADMSCs, cells were exposed to osteogenic and adipogenic differentiation medium, as previously described (23). For osteogenic differentiation, cells were cultured in high-glucose Dulbecco’s Modified Eagle Medium (DMEM; cat. no. G4510, Wuhan Servicebio Technology Co., Ltd.) containing 10% fetal bovine serum (FBS; cat. no. 11011; Zhejiang Tianhang Biotechnology Co., Ltd.), 200 μM L-ascorbic acid (cat. no. A8101; Beijing Solarbio Science & Technology Co., Ltd.), 0.1 μM dexamethasone (cat. no. D37736; Shanghai Aladdin Biochemical Technology Co., Ltd.) and 10 mM β-glycerol phosphate disodium pentahydrate (cat. no. G9140; Beijing Solarbio Science & Technology Co., Ltd.) at 37˚C for 21 days. Control cells were cultured in high-glucose DMEM containing 10% FBS. Cells were fixed with 4% paraformaldehyde (cat. no. C10488; Shanghai Aladdin Biochemical Technology Co., Ltd.) for 15 min at room temperature. Alizarin red staining solution at 1% concentration (cat. no. G1452; Beijing Solarbio Science & Technology Co., Ltd.) was added for 20 min at room temperature.

For adipogenic differentiation, Oil Red O Stain kit (cat. no. G1262; Beijing Solarbio Science & Technology Co., Ltd.) was used according to the manufacturer’s instructions. Cells were cultured in low-glucose DMEM (cat. no. G4520; Wuhan Servicebio Technology Co., Ltd.) containing 10% fetal bovine serum (FBS; cat. no. 11011; Zhejiang Tianhang Biotechnology Co., Ltd.), 100 μM L-ascorbic acid, 1 μM dexamethasone, 0.5 mM 1-methyl-3-isobutyl xanthine (cat. no. 1106812; Shanghai Aladdin Biochemical Technology Co., Ltd.), 100 μM indomethacin (cat. no. HY-14397, MedChemExpress) and 10 μg/ml human recombinant insulin (cat. no. INS-100MG; Bioing Biotech, China) at 37˚C for 21 days. Control cells were cultured in low-glucose DMEM containing 10% FBS at 37˚C for 21 days. The newly prepared Oil Red O staining solution was added for 20 min at room temperature. Isopropl alcohol (60%; cat. no. I112011; Shanghai Aladdin Biochemical Technology Co., Ltd.) was used for washing. Finally, cells were soaked in Oil red O buffer for 1 min at room temperature. Images were captured using a fluorescence microscope (200x, cat. no. IX-53; Olympus Corporation).

Cell treatment. Cells were treated with DMEM/F12 (cat. no. BL305A; Biosharp Life Sciences) containing 10 μM
5-Azacytidine (5-Aza; cat. no. A100625; Shanghai Aladdin Biochemical Technology Co., Ltd.) for 24 h at 37˚C. Treatment 1: After washing twice with PBS (cat. no. B548117; Sangon Biotech Co., Ltd.), cells were cultured in DMEM/F12 without 5-Aza for 14 days at 37˚C. Ghrelin at different concentrations (1, 5, 10, 50 and 100 nM; cat. no. GI11460; Shanghai Aladdin Biochemical Technology Co., Ltd.) was added to some group. Treatment 2: After washing twice with PBS, cells were cultured in 5-Aza-free DMEM/F12 for 7 days at 37˚C. In the ghrelin group, 10 nM ghrelin was added when the medium was changed to 5-Aza-free. Thereafter, cells were cultured for another 7 days at 37˚C. Treatment 3: After washing twice with PBS, cells were cultured in DMEM/F12 without 5-Aza for 14 days at 37˚C. To examine the effect of ghrelin and SFRP4, ghrelin (10 nM) and recombinant human SFRP4 (100 ng/ml; cat. no. 120-50; PeproTech, Inc.) were added when the medium was changed to 5-Aza-free.

RNA extraction and sequencing (seq). RNA-seq was performed 14 days later. Paired-end sequencing was performed. Total RNA was extracted from cells using TRIzol® (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. RNA quality was determined using a Nanodrop (Micro-Drop; Shanghai Baoyude Scientific Instrument Co., Ltd.) and the integrity was assessed using Fragment Analyzer 5400 (Agilent Technologies, Inc.). cDNA fragments of 250-300 bp were selected preferentially and the sequencing was directed from 5' to 3' end. Then, sequencing libraries were generated using NEBNext® Ultra™ RNA Library Prep kit for Illumina® (cat. no. E7530L; New England Biolabs) according to the manufacturer's instructions. The loading concentration of final library in different cell sample was different (2 to 4 nM). After library construction, the concentration was quantified by CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.). Finally, libraries were sequenced by NovaSeq 6000 S4 Reagent kit v1.5 (300 cycles; cat. no. 20028312; Illumina, Inc.) based on an Illumina Novaseq 6000 platform and 150 bp paired-end reads were generated. The quality of raw sequencing data was assessed by Fastp (version 0.23.1; https://github.com/OpenGene/fastp). Trimmed sequence reads were mapped to human reference genome (GRCh38/hg38; https://genome.ucsc.edu/) using hisat2 (daehwankimlab.github.io/hisat2/) with default parameters.

Bioinformatics analysis. Principal component analysis (PCA) and volcano plot were analyzed by ggplot2 package (Version: 3.4.1) in R (http://www.R-project.org/). Hierarchical clustering was analyzed by heatmap package (Version: 1.0.12) in R. Gene Ontology (GO; http://geneontology.org/) and Kyoto Encyclopedia of Genes and Genomes (KEGG; https://www.kegg.jp/) enrichment analysis of differentially expressed genes (DEGs) were analyzed using ClusterProfiler package (Version 4.2.2, Bioconductor platform; https://bioconductor.org/packages/releases/bioconductor/clusterProfiler.html) in R. DEGs were selected by Log2(Ifold-change)>1 and P<0.05.

Lentivirus infection. Coding sequence of the human DDX17 gene (NM_006386; National Institutes of Health) was inserted into pLJM1-EGFP (cat. no. ZT101; Hunan Fenghui Biotechnology Co., Ltd.) plasmid at the Nhel and AgeI restriction sites. pLJM1-EGFP-DDX17 or its empty vector plasmid was transfected into 293T cells [cat. no. iCell-h237 Saibaikang (Shanghai) Biotechnology Co., Ltd.] using Lipofectamine® 3000 (cat. no. L3000015; Invitrogen; Thermo Fisher Scientific, Inc.) to produce lentivirus particles, according to the manufacturer’s protocols. The second-generation lentiviral packaging system was used. Briefly, two solutions were prepared containing 24 µl Lipofectamine 3000 and 500 µl Opti-MEM (cat. no. 31985070; Invitrogen, Thermo Fisher Scientific, Inc.) or 8 µg lentiviral plasmid, 6 µg packaging vector (psPAX2; cat. no. 12260, Addgene, Inc.), 2 µg envelope (pMD2.G; cat. no. 12259, Addgene, Inc.), 28 µl Lipofectamine 3000 and 500 µl Opti-MEM. The solutions were mixed and placed at room temperature for 15 min. The mixture was added to 293T cells (37°C; 6 h) and lentiviral particles were collected using a 0.45-µm filter membrane (Tianjin Jinteng Biochemical Technology Co., Ltd.) was added to some group. Polybrene (cat. no. BL628A; Biosharp Life Sciences) at 5 µg/ml was also added. Cells were cultured in a 5% CO2 incubator at 37°C for 24 h. After a further 48 h (5% CO2, 37°C), the cells were collected for subsequent experiments.

Western blotting. Total protein was extracted from cells by radio immunoprecipitation assay lysis buffer (cat. no. P0013B) and 1% PMSF (cat. no. ST506; both Beyotime Institute of Biotechnology) and the product was collected by centrifugation (4°C, 1,000 x g, 3 min). Nuclear protein was extracted using a nuclear protein extraction kit (cat. no. P0028; Beyotime Institute of Biotechnology). Protein quantification was performed using BCA detection kit (cat. no. P0009; Beyotime Institute of Biotechnology). Proteins (15 µl/lane, containing 15-30 µg protein) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (8% for proteins in 35 to 50 kDa, 10% for proteins in 50 to 75 kDa and 12% for proteins over 75 kDa; cat. no. P0015; Beyotime Institute of Biotechnology) and transferred to polyvinylidene fluoride membrane (cat. no. LC2005; Thermo Fisher Scientific, Inc.). The non-specific sites were blocked using 5% bovine serum albumin (BSA; cat. no. BS043; Biosharp Life Sciences) to avoid non-specific adsorption (1 h, room temperature). The membrane was incubated with the primary antibody at 4°C overnight, followed by incubation with horse-radish peroxidase-labeled goat anti rabbit (cat. no. SA00001-2) or mouse (both 1:10,000; cat. no. SA00001-1; both Wuhan Sanying Biotechnology) IgG at 37°C for 40 min. Enhanced chemiluminescence reagent (cat. no. E003; 7 Sea Biotech) was added to the membrane for 5 min. The gel was scanned and optical density of the target band was analyzed by gel image processing system (GEL-Pro-Analyzer software, version 4.0, Roper Technologies, Inc.). Antibodies were as follows: Rabbit GATA binding protein 4 (GATA4; 1:1,000; cat. no. A13756; ABclonal Biotech Co., Ltd.), α-myosin heavy chain (α-MHC; 1:20,000; cat. no. 22281-1-AP; Wuhan Sanying Biotechnology), ISL LIM homeobox 1 (ISL1; 1:1,000; cat. no. A0871; ABclonal Biotech Co., Ltd.), NK2 homeobox 5 (NK2; 1:1,000; cat. no. A5651; ABclonal Biotech Co., Ltd.), Troponin T2, cardiac type (TNNT2; 1:1,000; cat. no. 15513-1-AP; Wuhan Sanying Biotechnology), secreted frizzled-related protein 4 (SFRP4; 1:1,000; cat. no. A6502; ABclonal Biotech Co., Ltd.), secreted frizzled-related protein 4 (SFRP4; 1:1,000; cat. no. A7547; ABclonal Biotech Co., Ltd.), secreted frizzled-related protein 4 (SFRP4; 1:1,000; cat. no. A8028; ABclonal Biotech Co., Ltd.) and Troponin T2, cardiac type (TNNT2; 1:1,000; cat. no. A8073; ABclonal Biotech Co., Ltd.).
LIU et al: GHRELIN PROMOTES ADMSC CARDIAC-DIFFERENTIATION

1:1,000; cat. no. A4189; ABclonal Biotech Co., Ltd.), Dead-box helicase 17 (DDX17; 1:1,000; cat. no. DF12935; Affinity Biosciences), β-catenin (1:1,000; cat. no. A19657; ABclonal Biotech Co., Ltd.), Histone H3 (1:500; cat. no. 17168-1-AP; Wuhan Sanying Biotechnology) and mouse β-actin (1:2,000; cat. no. 60008-1-Ig; Wuhan Sanying Biotechnology).

**Immunofluorescence (IF) staining.** Cells were fixed in 4% paraformaldehyde (cat. no. 80096618; Sinopharm Chemical Reagent Co., Ltd.) for 15 min at room temperature. Then, 0.1% triton X-100 (cat. no. ST795; Beyotime Institute of Biotechnology) was added for 30 min at room temperature. BSA (cat. no. A602440-0050; Sangon Biotech Co., Ltd.) was added as the blocking buffer at room temperature for 15 min. The primary antibody was diluted in PBS and incubated overnight at 4°C. Cy3-labeled goat anti-rabbit IgG (1:200; cat. no. A27039; Invitrogen; Thermo Fisher Scientific, Inc.) was added for 60 min at room temperature in the dark. For double IF staining, Cy3-labeled goat anti-rabbit (red; 1:200; cat. no. A27039; Invitrogen; Thermo Fisher Scientific, Inc.) and FITC-labeled goat anti-mouse IgG (green; 1:200; cat. no. ab6785; Abcam) were used as the secondary antibody. DAPI (cat. no. D106471; Shanghai Aladdin Biochemical Technology Co., Ltd.) was used for nuclear counterstaining (5 min, room temperature). After adding anti-fluorescence quencher (cat. no. S2100; Beijing Solarbio Science & Technology Co., Ltd.), images were captured under a fluorescence microscope (magnification, x400; DP73 system; Olympus Corporation). Antibodies were as follows: Mouse GATA4 (1:50; cat. no. sc-25310; Santa Cruz Biotechnology, Inc.) and GATA binding protein 4; MHC, myosin heavy chain; ISL1, ISL LIM homeobox 1; Nkx2.5, NK2 homeobox 2; TNNT2, Troponin T2, cardiac type.

Figure 1. Ghrelin promotes cardiomyocyte differentiation of ADMSCs. (A) Protein expression and (B) quantification of cardiomyocyte markers in ghrelin (1, 5, 10, 50 and 100 nM)-treated ADMSCs. (C) Immunofluorescence staining of GATA4 (green) and α-MHC (red) in ADMSCs. Scale bar, 50 µm. Data are expressed as mean ± SD (n=3). *P<0.05, **P<0.01 vs. control; ##P<0.01 vs. induction. ADMSC, adipose tissue-derived mesenchymal stem cell; GATA4, GATA binding protein 4; MHC, myosin heavy chain; ISL1, ISL LIM homeobox 1; Nkx2.5, NK2 homeobox 1; TNNT2, Troponin T2, cardiac type.
Rabbit α-MHC (1:100; cat. no. 22281-1-AP; Wuhan Sanying Biotechnology) and β-catenin (1:100; cat. no. A19657; ABclonal Biotech Co., Ltd.).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted using TRIpure isolation reagent (cat. no. RP1001; BioTeke Corporation) and the product was collected by centrifugation (4°C, 10,000 x g, 10 min). RNA concentration was measured by a UV spectrophotometer (Nano 2000; Thermo Fisher Scientific, Inc.). The RNA samples were reverse-transcribed to obtain the corresponding cDNA by BeyoRT II M-MLV reverse transcriptase (cat. no. D7160L; Beyotime Institute of Biotechnology) and RNase inhibitor (cat. no. B600478; Sangon Biotech Co., Ltd.). RT-qPCR was performed using SYBR GREEN (cat. no. SY1020; Beijing Solarbio Science & Technology Co., Ltd.) and 2XTaq PCR MasterMix (cat. no. PC1105; Beijing Solarbio Science & Technology Co., Ltd.) with the following thermocycling conditions: 95°C for 5 min, followed by 40 cycles of 95°C for 10 sec, 60°C for 10 sec and 72°C for 15 sec. Exicycler TM 96 fluorimeter (Bioneer Corporation) was used for fluorescence quantitative analysis. Results were calculated using 2^(-ΔΔCq) method (24). β-actin was the internal control. Primers were as follows: secreted frizzled-related protein 4 (SFRP4) forward, 5'-CAG CAC GCA GGA GAA CG-3' and reverse, 5'-GCA CGG CTT GAT AGG GTC-3'; thyroid hormone receptor interactor 6 (TRIP6) forward, 5'-GCT GGA TAG GCT GAC GAA GA-3' and reverse, 5'-GCG ATC AAG GGC CAC AAC-3'; Dead-box helicase 17 (DDX17) forward, 5'-GTG TTT GCC TTC CAT CAT-3' and reverse, 5'-TCT TCCAGAGCCAGTC-3'; cellular communication network factor 1 (CCN1) forward, 5'-AGTGGGTCTGATCGAGAAGA-3' and reverse, 5'-GGGACGGCCACCAAGGAGTA G-3' and reverse, 5'-ACAGGGAGCCGCTTCAGT-3'; SRY-box transcription factor 30 (SOX30) forward, 5'-AAA GAA ACC CTA TTA CGA TG-3' and reverse 5'-GGC TTG GGC TCT GGA CTA TTA CGA TG-3' and reverse, 5'-GGGATGGGCTCTGGACT-3'; tripartite motif containing 36 (TRIM36) forward, 5'-CTT GAT AAA TTG GCA CCA T-3' and reverse, 5'-GGA CTA CAG ATT GAA CCC T-3'; WNK lysine deficient protein kinase 1 (WNK1) forward, 5'-AAGCAAGCCTTCTAATG-3' and reverse, 5'-TGT GATACTGTAAACTACGC-3'; transcription factor 3 (TCF3) forward, 5'-GGAGCACAGGTGAACGG-3' and reverse, 5'-AACGG TGCTGGAGAGGAAGT-3' and β-actin forward, 5'-CCTGG GTAACACACAT-3' and reverse, 5'-TAATGTCAAGCA CGATTCC-3'.

**P<0.01 vs. control; ***P<0.01 vs. induction. ADMSC, adipose tissue-derived mesenchymal stem cell; SFRP4, secreted frizzled-related protein 4.
Statistical analysis. Data are presented as the mean ± SD from three independent experiments. Statistical analysis was performed using Graphpad Prism 8.0 software (GraphPad Software, Inc.; Dotmatics). Unpaired t test (Fig. 5) and one-way ANOVA followed by Dunnett’s multiple comparisons test (Figs. 1B, 2B and C) or Tukey’s multiple comparisons test (Figs. 6A, B, C, E, 7A and C) were performed. P<0.05 was considered to indicate a statistically significant difference.

Results

Ghrelin promotes cardiomyocyte differentiation of ADMSCs. ADMSCs were characterized by flow cytometry and multilineage differentiation. ADMSCs were positive for CD90, CD44 and CD29 and negative for CD45, CD34 and CD11 (Fig. S1A). Osteogenic (Fig. S1B) and adipogenic (Fig. S1C) induction were used to confirm the multilineage differentiation of ADMSCs. The differentiation ability of ADMSCs into cardiomyocyte was assessed by measuring the expression of cardiomyocyte markers such as GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2. Induction medium enhanced the expression of these markers in ADMSCs compared with the control and the addition of ghrelin further enhanced this in a concentration-dependent manner (Fig. 1A and B). Based on this, ghrelin at 10 nM was selected for subsequent experiments.

Ghrelin promotes cardiomyocyte differentiation of ADMSCs via regulation of SFRP4/Wnt/β-catenin axis. β-catenin expression was enhanced in induced ADMSCs compared with control cells and ghrelin further increased this trend (Fig. 2A).
IF staining was performed to determine localization of β-catenin. The red fluorescence of β-catenin was enhanced following induction (Fig. 2B). This was further enhanced by ghrelin and primarily localized in the nucleus, evidenced by the overlapping blue fluorescence with DAPI. Protein expression of SFRP4, an inhibitor of Wnt signaling pathway, was assessed. SFRP4 showed increased expression in induced cells compared with control and the addition of ghrelin partially reversed this effect (Fig. 2C). These results showed that ghrelin promoted activation of the Wnt/β-catenin signaling pathway in ADMSC cardiomyocyte differentiation by inhibiting SFRP4.

**DEGs and functional enrichment analysis of RNA-seq.** To confirm the role of ghrelin in the cardiomyocyte differentiation process of ADMSCs, RNA-seq of cultured ADMSCs was performed. To assess the consistency and variance of cell samples, PCA and hierarchical clustering were performed. PCA showed clear clustering in the induction and induction + ghrelin groups (Fig. 3A), which was also supported by hierarchical clustering results (Fig. 3B). Up- and downregulated DEGs (Fig. 3C) were annotated with GO and KEGG for functional analysis (Fig. 4A). GO was sorted into three primary functional categories: Biological process (BP), cellular component (CC) and molecular function (MF). Top 20 terms of BP were associated with ‘mesenchyme development’, ‘heart morphogenesis’, ‘mesenchymal cell differentiation’ and ‘muscle cell proliferation’; CC was associated with ‘transcription regulator complex’ and ‘perikaryon’; MF was associated with ‘Wnt-protein binding’, ‘Wnt-activated receptor activity’ and ‘transcription regulator inhibitor activity’. Top 20 terms of KEGG were primarily associated with ‘pathways in cancer’, ‘cytokine-cytokine receptor interaction’, ‘MAPK signaling pathway’. Key GO terms (Fig. 4B) and KEGG pathways (Fig. 4C) associated with mesenchymal cell differentiation and Wnt pathways are displayed.

Potential genes that regulated by ghrelin in the process of the cardiomyocyte differentiation of ADMSCs. Based on the results of RNA-seq, the present study investigated genes that...
were associated with the Wnt/β-catenin signaling pathway, including TRIP6 (25,26), SOX30 (27,28), TRIM36 (29,30), DDX17 (31-33), WNK1 (34,35), TCF3 (36) and CCN1 (37). All of these genes have been reported to be associated with activation or inhibition of the Wnt signaling pathway in previously reported studies. For verification, mRNA levels of these genes in cultured cells were measured. Ghrelin enhanced mRNA expression of TRIP6, DDX17 and CCN1 and suppressed the levels of SOX30 and TRIM36 (Fig. 5A). WNK1 and TCF3 exhibited no significant difference. Among these five changed genes, DDX17 has been reported to promote the expression of myocyte enhancer factor 2C (MEF2C) and TNNT1 in myoblast cells (38). Therefore, the present study detected the protein expression of DDX17 in ADMSCs. Ghrelin enhanced the protein expression of DDX17 (Fig. 5B). Accordingly, it was hypothesized that DDX17 may be involved in ghrelin-induced cardiomyocyte differentiation of ADMSCs.

**DDX17 promotes ADMSC cardiomyocyte differentiation and β-catenin nuclear accumulation.** To explore whether DDX17 was involved in ADMSC cardiomyocyte differentiation, DDX17 was overexpressed in ADMSCs and confirmed by RT-qPCR and western blotting (Fig. 6A and B). Then, protein expression of GATA4 and α-MHC was assessed in ADMSCs to verify the effect of DDX17 on Wnt/β-catenin signaling pathway activation. DDX17 overexpression caused enhanced protein expression and nuclear accumulation of β-catenin in ADMSCs (Fig. 6E and F). This demonstrated that enhanced expression of DDX17 may participate in ghrelin-induced Wnt/β-catenin signaling in cardiomyocyte differentiation of ADMSCs.

The present study detected the expression of β-catenin to verify the effect of DDX17 on Wnt/β-catenin signaling pathway activation. DDX17 upregulation caused enhanced protein expression and nuclear accumulation of β-catenin in ADMSCs (Fig. 6E and F). This demonstrated that enhanced expression of DDX17 may participate in ghrelin-induced Wnt/β-catenin signaling in cardiomyocyte differentiation of ADMSCs.

**DDX17, upregulated by ghrelin, promotes ADMSC cardiomyocyte differentiation by downregulating SFRP4.** The present study investigated the potential regulatory mechanism between DDX17 and Wnt/β-catenin signaling pathway activation. Protein expression of SFRP4 in ADMSCs was assessed; DDX17 overexpression decreased protein expression levels of SFRP4 (Fig. 7A). This demonstrated that DDX17 downregulated protein expression of SFRP4.

To determine the participation of DDX17 and SFRP4 in ghrelin-induced cardiomyocyte differentiation of ADMSCs, protein expression of cardiomyocyte markers following SFRP4 addition was detected. Ghrelin promoted the protein expression levels of GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2 (Fig. 7B and C). However, the addition of SFRP4 reversed this effect and the expression levels of GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2 were significantly decreased. IF staining of α-MHC also showed that SFRP4 abolished the enhanced expression of α-MHC (Fig. 7D). This indicated that DDX17...
was involved in ghrelin-induced ADMSC cardiomyocyte differentiation by downregulating SFRP4.

Discussion

MSCs serve key roles in tissue repair and regeneration and have been studied in cardiovascular disease (39,40), including myocardial infarction (MI) (41,42). ADMSCs differentiate into cardiomyocyte-like cells and are one of the ideal cell sources for myocardial regenerative medicine (2); compared with other types of MSC, ADMSCs are abundant, easy to obtain (43) and free from ethical concerns (44). These advantages make ADMSCs a candidate in clinical application. Several studies have reported that ADMSCs injected into animal myocardium post-MI results in improved cardiac function compared with untreated rats (45,46) or mice (47), as well as less fibrosis and wall thinning (48,49). However, the therapeutic efficacy of transplanted MSCs is limited by their poor engraftment and low survival rate in the injured tissues (50-52). Therefore, accelerating the differentiation of MSCs into cardiomyocytes.
may help to facilitate their clinical application. In the present study, ghrelin promoted differentiation of ADMSCs into cardiomyocyte via activation of the Wnt/β-catenin pathway. DDX17, an upregulated DEG following ghrelin addition, promoted the protein expression of cardiac-specific markers and β-catenin and inhibited expression of SFRP4. The present

Figure 7. DDX17, upregulated by ghrelin, promotes ADMSC cardiomyocyte differentiation by downregulating SFRP4. (A) Protein expression of SFRP4 in DDX17-overexpressing ADMSCs. *P<0.01 vs. LV-Empty. (B) Protein expression and (C) quantification of GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2. (D) Immunofluorescence staining of α-MHC in ADMSCs. Scale bar, 50 µm. Data are expressed as mean ± SD (n=3). *P<0.05, **P<0.01 vs. control; ***P<0.01 vs. induction; ****P<0.01 vs. induction + ghrelin. DDX17, Dead-box helicase 17; ADMSC, Adipose tissue-derived mesenchymal stem cell; SFRP4, secreted frizzled-related protein 4; LV, lentivirus; GATA4, GATA binding protein 4; MHC, myosin heavy chain; ISL1, ISL LIM homeobox 1; Nkx2.5, NK2 homeobox 5; TNNT2, Troponin T2, cardiac type.
study showed that DDX17 was involved in ghrelin-induced cardiomyocyte differentiation of ADMSCs, which was associated with regulation of the SFRP4/Wnt/β-catenin axis (Fig. 8). This provides a scientific foundation for the effect of ghrelin in cardiac differentiation of ADMSCs and application in clinical treatment.

Ghrelin, a gastric-secreted peptide hormone, is involved in multilineage differentiation of MSCs (12,53,54), including bone marrow-derived MSCs (55). Our previous study showed that ghrelin serves a critical role in the promotion of neural differentiation of ADMSCs (9). Another study has showed that intramyocardial injection of ADMSCs combined with ghrelin inhibits host cardiomyocyte apoptosis and improves cardiac function, in a mice myocardial infarction model (56). Therefore, it was hypothesized that ghrelin may also participate in cardiomyocyte differentiation of ADMSCs. The present results showed that ghrelin promoted expression of cardiac-specific markers GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2. This result implied that ghrelin promoted cardiomyocyte differentiation of ADMSCs. After confirming the positive effect of ghrelin on differentiation of ADMSCs into cardiomyocyte, the present study explored the underlying mechanism. In previously reported studies, Wnt/β-catenin pathway was confirmed to serve a critical role in the promotion of neural differentiation of ADMSCs (9). Another study has showed that intramyocardial injection of ADMSCs combined with ghrelin inhibits host cardiomyocyte apoptosis and improves cardiac function, in a mice myocardial infarction model (56). Therefore, it was hypothesized that ghrelin may also participate in cardiomyocyte differentiation of ADMSCs. The present results showed that ghrelin promoted expression of cardiac-specific markers GATA4, α-MHC, ISL1, Nkx2.5 and TNNT2. This result implied that ghrelin promoted cardiomyocyte differentiation of ADMSCs. After confirming the positive effect of ghrelin on differentiation of ADMSCs into cardiomyocyte, the present study explored the underlying mechanism. In previously reported studies, Wnt/β-catenin pathway was confirmed to serve an important role in cardiomyocyte differentiation and cardiac formation (57,58). A previous study suggested that Wnt/β-catenin regulates the crucial transcription factors as Baf60c, Nkx2.5 and ISL1 at an early stage of progenitor formation (59). The aforementioned results demonstrate that the regulation of Wnt/β-catenin pathway is key during cardiomyocyte differentiation. Similarly, ghrelin promotes neural SC differentiation via the Wnt/β-catenin pathway (60). Ghrelin can regulate apoptosis in cells and tissue by regulating the Wnt/β-catenin pathway (61,62). Therefore, it was hypothesized that the positive effect of ghrelin on cardiomyocyte differentiation of ADMSCs may be associated with the Wnt/β-catenin pathway. The present study found that ghrelin significantly promoted expression of nuclear β-catenin, thus enhancing the activity of the aforementioned signaling pathway. In addition, studies have reported that SFRP4, an inhibitor of the Wnt/β-catenin pathway, inhibits the expression of cardiac-specific genes during cardiomyocyte differentiation of P19CL6 cells (22). Knockdown of SFRP4 attenuates apoptosis to protect against myocardial ischemia/reperfusion injury (63). Therefore, the expression of SFRP4 was also tested; ghrelin inhibited the elevated SFRP4 protein expression in ADMSCs. Therefore, it was hypothesized that ghrelin may promote cardiomyocyte differentiation of ADMSCs by regulating the SFRP4/Wnt/β-catenin axis.
To determine the role of ghrelin in ADMSCs, cells were subjected to RNA-seq to determine the genes regulated by ghrelin. Expression of numerous genes changed following ghrelin treatment. Following screening, TRIP6, SOX30, TRIM36, DDX17, WNK1, TCF3 and CCN1 were selected for further study; these genes were associated with the Wnt/β-catenin signaling pathway. Among these genes, TRIP6 (25,26), DDX17 (31-33), WNK1 (34,35) and CCN1 (37) are associated with the activation of the Wnt/β-catenin pathway and SOX30 (27,28), TRIM36 (29,30) and TCF3 (36) are associated with its inhibition. DDX17 has been reported to promote mRNA expression of myocyte enhancer factor 2C (MEF2C) and TNNT1 in myoblast cells (38) and serve a protective role in doxorubicin-induced cardiomyocyte injury (64). Therefore, DDX17 was selected for further study. Here, DDX17 overexpression showed a similar effect to ghrelin in promoting the cardiomyocyte differentiation of ADMSCs and Wnt/β-catenin signaling pathway activation. More importantly, the present results showed that DDX17 downregulated SFRP4 expression. Rescue assay was performed to determine the role of SFRP4. SFRP4 reversed the promoting effect of ghrelin on cardiomyocyte differentiation of ADMSCs, which demonstrated the participation of DDX17 in this process.

The present study demonstrated that ghrelin promoted cardiomyocyte differentiation of ADMSCs. However, there are limitations. First, RNA-seq indicated that the promotive effect of ghrelin may be related to DDX17-mediated regulation of the SFRP4/Wnt/β-catenin axis. However, the expression of numerous genes was significantly changed following ghrelin treatment, including 456 up- and 470 downregulated genes. Therefore, ghrelin may promote cardiomyocyte differentiation of ADMSCs by regulating other genes. Second, based on the critical role of the Wnt/β-catenin pathway in cardiomyocyte differentiation, the present study focused on the connection between ghrelin and activation of the Wnt/β-catenin pathway. However, TGF-β (65) and Notch (66,67) signaling pathways also serve an important role in cardiomyocyte differentiation. Therefore, the promoting effect of ghrelin on cardiomyocyte differentiation of ADMSCs may not be solely dependent on the Wnt/β-catenin pathway. Third, the present study mainly focused on the effect of ghrelin on cardiomyocyte differentiation of ADMSCs in vitro; effects of ghrelin in vivo need to be determined.

In conclusion, the present study indicated that ghrelin promoted differentiation of ADMSCs into cardiomyocytes by DDX17-mediated regulation of the SFRP4/Wnt/β-catenin axis. Specifically, ghrelin promoted cardiomyocyte differentiation of ADMSCs via activation of the Wnt/β-catenin pathway. DDX17, an upregulated DEG, enhanced protein expression of cardiac-specific markers and β-catenin and inhibited the expression of SFRP4. The present results provide scientific foundation for the effect of ghrelin in cardiac-differentiation of ADMSCs and may assist to promote the application of ghrelin in the ADMSCs mediated clinical treatment of cardiac-associated injury.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Joint Guidance Project of Natural Science Foundation of Heilongjiang Province (grant no. LH2020H074) and the Scientific Research Project of Basic Scientific Research Business Expenses of Provincial Colleges and Universities in Heilongjiang Province (grant number 2020-KYYWF-0780).

Availability of data and materials
The datasets generated and analyzed during the current study are available in the NCBI Gene Expression Omnibus repository, ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE232876 (accession no. GSE232876).

Authors’ contributions
GBL conceived the study, designed the experiments, collected data and wrote the manuscript. YXC conceived the study, designed the experiments and wrote the manuscript. HML and YL collected, analyzed and clarified the data. LXS and QW designed the experiments and performed the literature review. SFG and TTL analyzed and interpreted data and performed the literature review. CLD collected data and performed the literature review. GS conceived and supervised the study, designed the experiments and reviewed the manuscript. GBL and GS confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

References
Rapamycin promotes cardiomyocyte differentiation of adipose tissue-derived mesenchymal stem cell via AKT/mTOR and β-catenin signaling pathways.

SOX30 inhibits tumor metastasis through attenuating Wnt-signaling via transcriptional and posttranslational regulation of β-catenin in lung cancer.

Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left cardiac remodelling post experimentally induced myocardial infarction in diabetic db/db mice.


